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Summary
Lipocortin-1 (annexin-1) is an endogenous peptide with antiinflammatory properties . We have
previously demonstrated lipocortin immunoreactivity in certain glial cells and neurons in the
rat brain (Strijbos, P. J . L . M ., F. J. H . Tilders, F. Carey, R . Forder, andN . J . Rothwell . 1990 .
Brain Res. In press .), and have shown that an NH2-terminal fragment (1-188) of lipocortin-1
inhibits the central and peripheral actions of cytokines on fever and thermogenesis in the rat
in vivo (Carey, F., R. Forder, M . D. Edge, A . R . Greene, M . A. Horan, P J . L . M . Strijbos,
andN . J . Rothwell . 1990 . Am.J . Physiol. 259:R266; and Strijbos, P J. L .M ., J. L . Browning,
M . Ward, R. Forder, F. Carey, M. A . Horan, and N . J . Rothwell . 1991 . Br .J. Pharmacol. In
press .) . Wenow report that intracerebroventricular administration of lipocortin-1 fragment causes
marked inhibition of infarct size (60%) and cerebral edema (46%) measured 2 h after cerebral
ischemia (middle cerebral artery occlusion) in the rat in vivo. The lipocortin-1 fragment was
effective when administered 10min after induction ofischemia. Ischemia caused increased expression
of lipocortin-1 around the area of infarction as demonstrated by immunocytochemistry. Intra-
cerebroventricular injection of neutralizing antilipocortin-1 fragment antiserum increased the
size ofinfarct (53%) and the development ofedema (29%) . These findings indicate that lipocortin-1
is an endogenous inhibitor of cerebral ischemia with considerable therapeutic potential .
L
ocortins are a family of calcium binding proteins with
diverse actions, including antiinflammatory properties,
possibly acting by inhibition of arachidonic acid production
and subsequent reduction in eicosanoid synthesis (see refer-
ence 1) . However, there is now some doubt over their mech-
anisms ofaction (2), and several have been demonstrated ; e.g.,
phospholipid binding, calcium binding, and receptor phos-
phorylation (see references 3 and 4) . Nevertheless, potent an-
tiinflammatory effects of lipocortin-1 have been demonstrated
on carrageenin-induced paw edema in the rat in vivo (5) .
Lipocortins have been proposed as mediators of glucocorti-
coid actions, and their synthesis can be induced by endoge-
nous or synthetic steroids (see reference 1), although in some
tissues lipocortin induction appears to be independent of glu-
cocorticoid status (6) .
Several reports have indicated that lipocortin-1 is present
in the brain (7-9), and we have described its cellular distri-
bution in the rat brain in some detail (10) . A high density
of lipocortin-l-like immunoreactivity is present in both glial
and neuronal cells throughout thebrain, with the latter most
evident in the dentate gyrus, CA1, CA2, and CA3 neurones
of the hippocampus . Central administration ofan active recom-
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binant fragment (1-188 amino acids) of lipocortin-1 causes
dose-dependent inhibition of the actions ofcytokines on fever
and metabolism in the conscious rat (11). Inhibition of the
actions of endogenous lipocortin-1 within the brain, by ce-
rebral injections of neutralizing antibody raised to the
lipocortin-1 fragment, significantly reverses the inhibitory
effects of glucocorticoids on cytokine action (11) . These ob-
servations indicate that both endogenous and exogenous
lipocortin-1 have important biological actions within the cen-
tral nervous system .
Interruption of blood supply to the brain (cerebral isch-
emia) results in damage to neurones within the central nervous
system, ultimately leading to cell death . The mechanisms of
this neurodegenerative process are not fully understood, but
apparently involve increased extracellular calcium concentra-
tions, release of excitatory amino acids, increased synthesis
of arachidonic acid and eicosanoids, and formation ofedema
(12) . Cytokines have also been strongly implicated in the neu-
rodegenerative responses to brain injury (13), although their
involvement in cerebral ischemia has not yet been investigated.
Modification of these processes provide possible targets for
therapeutic intervention, whichmay be ofbenefit in the treat-
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Volume 174 August 1991 305-310ment of stroke or brain injury. In view of the actions of
lipocortin-1 already described, it is likely that this peptide
could inhibit several of the events that ultimately lead to neu-
ronal death after ischemia.
The objective of the present study was to investigate the
effects of exogenous andendogenous lipocortin-1 on cell death
and edema formation after cerebral ischemia in the rat . The
results indicate that lipocortin-1 is a potent, endogenous in-
hibitor of brain damage which maybe of considerable ther-
apeutic benefit .
Materials and Methods
Cerebral Ischemia .
￿
Cerebral ischemia wasinducedby permanent
unilateral occlusion of the middle cerebral artery (MCA)' in
anesthetized rats. Young, adult (200-250 g), male SpragueDawley
rats (Charles River Breeding Laboratories, Kent,UK)were stereo-
taxically implanted with guide cannulae in the third ventricle of
the brain under pentobarbitone anesthesia at least 4 dbefore the
experiment .MCAocclusion (14) was performedunder halothane
(2% in oxygen, nitrous oxide) anesthesia . The left MCA was ex-
posed through a small sub-temporal craniectomy, andwas occluded
by electrocoagulation using bipolar diathermy at the point where
it crossed the olfactory tract, and at the level ofthe inferior cerebral
vein, a cutwas then made betweenthe points ofcoagulation . The
wound was sutured and recovery of consciousness in all animals
was achieved within 10 min of surgery.
Assessment of Infarct Volume.
￿
Rats were killed either 2 or 24
h afterMCA occlusion. Brains were removedand 500-1.1m coronal
sections cut, immediately placed individually into tetrazolium dye
staining medium, andincubated for 30 min at room temperature.
The positively stained area on each slicewas stereotaxically sketched
by eye and infarct area for each section assessed using Magiscan
2 image analysis .
Cerebral Edema .
￿
Tissue density of hemispheric brain sections
was assessed by percoll gradient (adapted from reference 15) . Animals
were killed 2 h afterMCA occlusion and their brains rapidly re-
moved. 1-mm sections were cut from each hemisphere at the level
ofbregma, andthe equilibriation depth of each slice in the percoll
gradient was measured after 2 min. The tissue water content of
each sample was calculated from the equilibrium depth that was
directly proportional to the specific gravity of the tissue.
Distribution ofLipocortin-1 in the Brain .
￿
Lipocortin-1 immunoreac-
tivity was determined using an antiserum raised in rabbits to a
recombinant lipocortin-1 fragment (1-188) (11) . We have demon-
stratedby Western blot analysis and gelatin models that this an-
tiserum binds to endogenous rat lipocortin-1 (1 ; and Carey et al .,
unpublished data) . Rats were killed, the brains rapidly removed
and immersion fixed (4% paraformaldehyde in 0.1 M phosphate
buffer), frozen, and 10-1.1m frontal sections cut . Sections were washed
with TBS at room temperature and incubated overnight at room
temperature with theprimary polyclonallipocortin-1 fragment an-
tiserum (1:100, with TBS containing 0.3% Triton X-100) . Im-
munoreactivity was visualized using FITC-labeled secondary an-
tiserum incubated for 1 h at room temperature. Control sections
were incubated with lipocortin-1 fragment antiserum (1:100) pre-
absorbed with an excess of lipocortin-i fragment (10-6 M, 22
ttg/ml) and showed no lipocortin-1 immunoreactivity.
Experimental Protocol.
￿
10 min afterMCA occlusion, rats were
injected intracerebrally with either lipocortin-1 fragment (human
1 Abbreviation used in this paper: MCA, middle cerebral artery.
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recombinant lipocortin-1, NHZ-terminal 1-188 amino acids) that
had been expressed in Escherichia coli (2) at a dose of 1.2 14g in 3
1.11PBS or sterile vehicle (0.9% saline) alone (controls) via a previ-
ously implanted indwelling guide cannula.
In separate experiments, animals were injected intracerebroven-
tricularly with either antiserum to the lipocortin-1 fragment or
nonimmune serum (31.11) using thesame protocol as above. Animals
were killed either 2 or 24 h after surgery for assessment of infarct
volume, after 2 h for cerebral edema, or after 7 d for lipocortin
distribution .
Statistical Analysis. Values are presented as means ± SEM.
Statisticaldifferences were assessed by Student's t test forunmatched
data using two-tailed probabilities throughout .
Results
MCA occlusion resulted in reproducible and extensive
damage to the striatum and cortex (assessed from tetrazo-
lium staining ofbrain slices), measured 2 h after surgery. No
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Figure 1.
￿
Effect oflipocortin-1 fragment on infarct size. Animals were
injected intracerebrmmtricularly with either saline (31.11/rat, n = 10) (circles)
or lipocortin-1 fragment (1.2 jug in 3 111/rat, n - 10) (squares) 10 min
after MCA occlusion and killed 2 h later to assess infarct area (mmz) .
Mean ± SEM, " = p < 0.05, " = p < 0.01 .
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Figure 2.
￿
Effect oflipocortin-1 fragment on infarct size. Examples taken
of coronal sections takenjust anterior to bregma from brains of animals
in the saline-treated (n = 4) and lipocortin-1 fragment-treated (n = 4)
groups 2 h after MCA occlusion (see Fig. 1) .E
E
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Figure 3.
￿
Effect of lipocortin-1 fragment antiserum on infarct size .
Animals were injected intracerebroventricularly with either nonimmune
serum (3 wl/rat, n = 10) (circles) or lipocortin-1 fragment antiserum (3
,1/rat, n - 10) (squares) 10 min afterMCA occlusion and killed 2 h later
to assess infarct area (mm3 ) . Mean t SEM, ' - p < 0.05.
damage was observed in any sham-operated animals (data not
shown) . A single intracerebroventricular injection of lipo-
cortin-1 fragment (1.2 wg/rat), 10 min after the induction
of cerebral ischemia, caused marked inhibition of this damage
assessed 2 h after surgery (Figs . 1 and 2) . The total volume
of the infarct was reduced by 60% (control, 32.03 ± 4.3
vs . lipocortin, 13.32 ± 3.6mm3 , n = 10, p < 0.05) . A very
similar pattern of infarction, although more extensive, was
observed when damage was assessed 24 h afterMCA occlu-
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Figure 4 .
￿
(a) Effect of lipocortin-1 fragment on cerebral edema . Animals were injected intracerebroventricularly with either saline (3 ul/rat, n -
10) or lipocortin-1 fragment (1.2 l+g in 3 u1/rat, n - 10) 10 min after MCA occlusion . Results are expressed as the difference in tissue density (gH20/ml
x 10-3) between left (damaged) and right (undamaged) hemisphere samples 2 h after MCA occlusion . Mean t SEM, " = p < 0.05 . (b) Effect of
lipocortin-1 fragment antiserum on cerebral edema. Animals were injected intracerebroventricularly with either nonimmune serum (3 A]/rat, n =
6) or lipocortin-1 fragment antiserum (3 pl/rat, n - 6) 10 min after MCA occlusion . 2 h later, animals were killed and tissue density assessed. Mean
± SEM, ' - p < 0.05.
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sion. Lipocortin-1 fragment, administered 10, 30, and 60 min
after ischemia, caused reductions in infarct volume assessed
24 h later of53%, 39%, and 27%, respectively (10 min con-
trol; 80.53 ± 13.2 vs . lipocortin; 37.9 t 6.1mm3 , n = 10,
p < 0.05), (30 min control; 94.79 ± 10.7 vs. lipocortin; 58.28
± 9.6, n = 10,p< 0.05), (60 min control 66.82 t 10.3
vs. lipocortin; 48.77 t 12.2, n = 10).
In a separate experiment, intracerebroventricular injection
ofantiserum to lipocortin-1 fragment, significantly increased
(53%) the extent ofneuronal damage (control ; 22.58 t 2.4
vs. lipocortin-As; 34.6 t 4.1 mm3 , n = 10, p < 0.05) as-
sessed 2 h after the induction of ischemia (Fig. 3) .
Cerebral edemawas assessed from tissue density, and ex-
pressed as the difference between the infarcted (left) and the
undamaged (right) hemisphere sections . Tissue density mea-
surements for undamaged right hemisphere sections were al-
most identical to values for both left and right hemisphere
samples from unoperated control animals (data not shown) .
In animals subjected to MCA occlusion and injected with
either saline or nonimmune serum, significant edema was
apparent within 2 h. Injection of the lipocortin-1 fragment
(1.2 hg/rat) caused significant (46%) inhibition of edema
without affecting the uninjured tissue (Fig . 4 a) (control ;
1.81 ± 0.25 x 10 -3 vs . lipocortin ; 0.98 ± 0.18 x 10 -3
gH20/ml, n = 10, p < 0.05) .
In contrast, administration oflipocortin antiserum (3 JA/rat)
enhanced the extent of edema in the infarcted hemisphere
by29% (Fig. 4 b) again, without affecting the uninjured tissue
(control; 1.68 ± 0.12 x 10-3 vs. lipocortin-As; 2.15 ± 0.32
x 10 -3 gH20/ml, n = 6) .
Immunohistochemical examination of brain tissue, 7 d after
the induction ofcerebral ischemia, revealed a marked increase
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bin lipocortin-1 immunoreactivity in infarcted areas of cortex
compared to undamaged tissue (Fig . 5) . No changes in
lipocortin-1 distribution were observed in the brains ofsham-
operated animals.
Discussion
The results of this study demonstrate that a recombinant
fragment of lipocortin-1 is a potent inhibitor of neuronal
damage and edema after cerebral ischemia in the rat, and fur-
ther suggest that endogenous lipocortin-1 may be induced
during ischemia and act to limit subsequent damage.
Research on cerebral ischemia is dependent upon the use
of surgical procedures in laboratory animals that are presumed
to have some direct relevance to clinical conditions of isch-
emia . The protocol carried out in the present study, unilateral
MCA occlusion in the rat, is widely recognized as one of
the most reliable, reproducible, and relevant experimental
models of focal ischemia currently practiced (see reference 16) .
Animals regain consciousness rapidly, with no overt behavioral
defects, and the location and type of damage is comparable
to that seen after ischemia in humans. A variety of methods
have been used to assess the extent of neurological damage
resulting from cerebral ischemia in experimental animals, some
of the most common of these are blood flow or tissue den-
sity measurement, behavioral evaluation, and histological as-
sessment . Tetrazolium chloride is a histochemical indicator
of mitochondrial respiratory enzymes, and was used in the
present study because of its ability to reliably delineate areas
of brain infarction at a gross anatomical level using fresh,
unfixed tissue samples (17) . The percoll density gradient used
in this study is an adaptation of that described by Marmarou
et al . (15), and applies the specific gravity method to quan-
tify the extent of cerebral edema. This type of gradient is
uniform and linear, and offers advantages over more conven-
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Figure 5 . Immunohistochemical
staining of lipocortin-1 in infarcted
tissue 7 d afterMCA occlusion . Light
staining indicates the presence of im-
munoreactive lipocortin-1 in the area of
infarction .
tional techniques involving weighing and drying since it is
both less time consuming and more precise .
The recombinant fragment oflipocortin-1 has similar bio-
logical activity to the full molecule both in vitro and in vivo
(18) . However, in studies to directly compare the effects of
the two molecules, we have demonstrated that the fragment
apparently has greater activity when administered intra-
cerebrally, probably due to improved availability to the brain,
and has the additional advantage of greater stability (18) . The
dose of the fragment used in the present study was based
on that which is maximally effective at inhibiting the central
actions ofcytokine-induced fever and hypermetabolism (11) .
However, since the site of action on ischemic brain tissue is
probably some distance from the third ventricle, it is likely
that higher doses, different sites of injection, or times of ad-
ministration may be more effective . The actions ofmany anti-
ischemic agents are improved considerably by administration
before the insult, and in some cases this is the only means
of obtaining significant effects (e.g., reference 19) . We have
observed potent effects on infarct size when lipocortin-1 frag-
ment is injected 10 min after the induction of ischemia, and
it is possible that further protection may be afforded by
pretreatment of animals with this molecule. Furthermore,
the results obtained from MCA-occluded animals 24 h after
a single dose of lipocortin-1 fragment demonstrate that the
protective effect of lipocortin does not appear to be a delay
in the manifestation of the neurological consequences of ce-
rebral ischemia, but rather a permanent inhibition of the de-
velopment of neuronal damage. The chronic effects of lipo-
cortin-1 fragment beyond 24 h after MCA occlusion have
not yet been studied .
The antilipocortin-1 fragment antiserum used in this study
is able to bind and neutralize both the fragment itself and
the full recombinant molecule (11) . Western blot analysis in-
dicates that it is also able to bind to endogenous lipocortinfrom the rat brain (Carey et al ., unpublished data) . It is there-
fore reasonable to assume that the potentiating effects of this
antiserum on neuronal damage and cerebral edema afterMCA
occlusion is a result ofthe inhibition ofendogenous lipocortin
within the rat brain . The observed increase in lipocortin-like
immunoreactivity in infarcted brain tissue (Fig. 5), although
preliminary, suggests that some factor associated with isch-
emic stimulates the synthesis of the molecule, which may
then serve as an endogenous inhibitor of neuronal damage.
We have also observed an increase in lipocortin-like im-
munoreactivity around the site of mechanical brain injury
in the rat (Strijbos et al., unpublished data) .
Glucocorticoids are potent inducers of lipocortin-1 in sev-
eral tissues and cell lines (4) . However, the synthetic gluco-
corticoid dexamethasone phosphate apparently does not
modify lipocortin-1 content ofrat brain (10) . These observa-
tions, together with the knowledge that glucocorticoids offer
little or no protection against ischemic brain damage (20),
indicate that the actions oflipocortin described here are not
related to glucocorticoid status or effects .
The mechanisms involved in the protective effect of
lipocortin-1 on ischemic tissue are unknown . Inhibition of
arachidonic acid release by lipocortin could decrease the syn-
thesis of eicosanoids and inhibit the release and actions of
the excitatoryamino acid glutamate (21, 22), both of which
may limit ischemic damage. Inhibition of the rise in intracel-
lular calcium, which is central to the chain ofischemic damage,
offers another possible site of action of lipocortin .
Research directed towards the treatment of stroke has, until
now, focussed on the inhibition ofthe mediators of neuronal
damage . The results presented here indicate that lipocortin-1
is an endogenous inhibitor of damage, and as such may offer
a new avenue for therapeutic intervention. It is postulated
that lipocortin may also be beneficial in myocardial ischemic
and other forms of neurodegeneration .
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